ExcelMab Inc. has completed a Series A+ financing round of tens of millions of RMB, with the participation of KIP , Cas Investment, Mefund Capital and Elite Capital.

ExcelMab Inc. is an innovative drug company focusing on the development of tumor immune bispecific antibodies, and has developed a number of biphasic products covering various indications such as breast cancer, gastric cancer, and chronic lymphocytic leukemia. This round of financing will be mainly used for the research and development of bispecific antibodies and the clinical trial filing of its bispecific antibodies for breast cancer.

    Founded in May 2016 by a team of returnees led by Dr. Wenjun Zhang in the Guangzhou Development Zone, ExcelMab specializes in the development and industrialization of bispecific antibodies, using its leading international proprietary BsAb platform, ExMab®.

    The ExMab® platform is one of the world's top bispecific antibody platforms. It uses structure-based protein engineering technology to fuse two different specific antibody molecules together to form a stable, low-immunogenicity drug, which is significantly better than other similar technologies in a variety of indicators. The advantages of this technology include simple production process, easy purification, high yield, and heterodimer expression rate of over 95%. 

    At present, there are only three bispecific antibody drugs available in the world, and there is no self-developed bispecific antibodies in China, which is greatly dependent on imported drugs. It can be said that bispecific antibodies are the most important development direction in China and international market, and even in the future for a long period of time, and it is also a very valuable market development field.

    The founder, Dr. Wenjun Zhang, has nearly 20 years of experience in the development of bispecific antibodies, and the company also has a team with rich technical and management experience, which provides a solid foundation and guarantee for the development of bispecific antibodies in Esmeralda.

    Dr. Wenjun Zhang, founder of Excelmab, said, "Thanks to the support and trust of our investors, we can continue to forge ahead on the road of BsAb drug development, and we will make every effort to promote the development of our products in the spirit of perfection, and strive to realize ExcelMab's long-held vision of developing highly effective antibody drugs that are affordable to patients around the world."

    At present, ExcelMba Inc. has developed EX101, an international leading dual antibodies molecule for breast cancer and gastric cancer, and the molecule will enter the preclinical stage soon and is expected to make IND filing at the end of this year.